David Jablons, MD

Chief of Thoracic Surgery

Dr. David M. Jablons is a renowned lung cancer expert, chief of General Thoracic Surgery at UCSF Medical Center and program leader of the Thoracic Oncology Program of the UCSF Helen Diller Family Comprehensive Cancer Center. He also is director of the UCSF Thoracic Oncology Laboratory where he is investigating molecular biology and genomics.

Jablons earned an undergraduate degree from Yale University and a medical degree from Albany Medical College of Union University. He completed a surgical residency at Tufts-New England Medical Center. He has written numerous research papers and frequently lectures about lung cancer at international and national meetings. He is a member of many professional organizations, including the American Association for Cancer Research, International Association for the Study of Lung Cancer, Society of Thoracic Surgeons and the American Association for the Advancement of Science.


Thoracic Surgery and Oncology
1600 Divisadero St., Fourth Floor
San Francisco, CA 94143-1705
Phone: (415) 885-3882
Fax: (415) 353-7151

Hours: Monday to Friday
8 a.m. – 5 p.m.

Conditions & Treatments

Board Certification

Thoracic and Cardiac Surgery, American Board of Thoracic Surgery

Academic Title


More about David Jablons

Additional Languages



Albany Medical College 1984


Tufts-New England Medical Center, General Surgery 1991


New York Hospital-Cornell University, Cardiothoracic Surgery 1993

Selected Research and Publications

  1. Leprieur EG, Tolani B, Li H, Leguay F, Hoang NT, Acevedo LA, Jin JQ, Tseng HH, Yue D, Kim IJ, Wislez M, Wang C, Jablons DM, He B. Membrane-bound full-length Sonic Hedgehog identifies cancer stem cells in human non-small cell lung cancer. Oncotarget. 2017 Nov 28; 8(61):103744-103757.
  2. Wang VE, Urisman A, Albacker L, Ali S, Miller V, Aggarwal R, Jablons D. Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden. J Immunother Cancer. 2017 Sep 19; 5(1):75.
  3. Dai Y, Jablons D, You L. Hippo pathway in lung development. J Thorac Dis. 2017 Aug; 9(8):2246-2250.
  4. Mendez P, Fang LT, Jablons DM, Kim IJ. Systematic comparison of two whole-genome amplification methods for targeted next-generation sequencing using frozen and FFPE normal and cancer tissues. Sci Rep. 2017 Jun 22; 7(1):4055.
  5. Woodard GA, Wang SX, Kratz JR, Zoon-Besselink CT, Chiang CY, Gubens MA, Jahan TM, Blakely CM, Jones KD, Mann MJ, Jablons DM. Adjuvant Chemotherapy Guided by Molecular Profiling and Improved Outcomes in Early Stage, Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2017 May 31.
  6. Wang H, Dai YY, Zhang WQ, Hsu PC, Yang YL, Wang YC, Chan G, Au A, Xu ZD, Jiang SJ, Wang W, Jablons DM, You L. DCLK1 is correlated with MET and ERK5 expression, and associated with prognosis in malignant pleural mesothelioma. Int J Oncol. 2017 Jul; 51(1):91-103.
  7. Kratz JR, Woodard G, Jablons DM. Management of Lung Cancer Invading the Superior Sulcus. Thorac Surg Clin. 2017 May; 27(2):149-157.
  8. Yoon JH, Kim TW, Mendez P, Jablons DM, Kim IJ. Mobile Genome Express (MGE): A comprehensive automatic genetic analyses pipeline with a mobile device. PLoS One. 2017; 12(4):e0174696.
  9. Dai Y, Liu S, Zhang WQ, Yang YL, Hang P, Wang H, Cheng L, Hsu PC, Wang YC, Xu Z, Jablons DM, You L. YAP1 regulates ABCG2 and cancer cell side population in human lung cancer cells. Oncotarget. 2017 Jan 17; 8(3):4096-4109.
  10. Li H, Yue D, Jin JQ, Woodard GA, Tolani B, Luh TM, Giroux-Leprieur E, Mo M, Chen Z, Che J, Zhang Z, Zhou Y, Wang L, Hao X, Jablons D, Wang C, He B. Gli promotes epithelial-mesenchymal transition in human lung adenocarcinomas. Oncotarget. 2016 Dec 06; 7(49):80415-80425.
  11. Kang HC, Kim JI, Chang HK, Woodard G, Choi YS, Ku JL, Jablons DM, Kim IJ. FAIM2, as a novel diagnostic maker and a potential therapeutic target for small-cell lung cancer and atypical carcinoid. Sci Rep. 2016 Sep 28; 6:34022.
  12. Woodard GA, Crockard JC, Clary-Macy C, Zoon-Besselink CT, Jones K, Korn WM, Ko AH, Gottschalk AR, Rogers SJ, Jablons DM. Hybrid minimally invasive Ivor Lewis esophagectomy after neoadjuvant chemoradiation yields excellent long-term survival outcomes with minimal morbidity. J Surg Oncol. 2016 Dec; 114(7):838-847.
  13. Dang J, Mendez P, Lee S, Kim JW, Yoon JH, Kim TW, Sailey CJ, Jablons DM, Kim IJ. Development of a robust DNA quality and quantity assessment qPCR assay for targeted next-generation sequencing library preparation. Int J Oncol. 2016 Oct; 49(4):1755-65.
  14. Hsu PC, You B, Yang YL, Zhang WQ, Wang YC, Xu Z, Dai Y, Liu S, Yang CT, Li H, Hu B, Jablons DM, You L. YAP promotes erlotinib resistance in human non-small cell lung cancer cells. Oncotarget. 2016 Aug 09; 7(32):51922-51933.
  15. Xu Y, Ding VW, Zhang H, Zhang X, Jablons D, He B. Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so far. Ther Clin Risk Manag. 2016; 12:807-16.
  16. Mendez P, Dang J, Kim JW, Lee S, Yoon JH, Kim T, Sailey CJ, Jablons DM, Kim IJ. Comprehensive evaluation and validation of targeted next-generation sequencing performance in two clinical laboratories. Int J Oncol. 2016 Jul; 49(1):235-42.
  17. Hung MS, Chen IC, You L, Jablons DM, Li YC, Mao JH, Xu Z, Lung JH, Yang CT, Liu ST. Knockdown of cullin 4A inhibits growth and increases chemosensitivity in lung cancer cells. J Cell Mol Med. 2016 Jul; 20(7):1295-306.
  18. Lui NS, Yang YW, van Zante A, Buchanan P, Jablons DM, Lemjabbar-Alaoui H. SULF2 Expression Is a Potential Diagnostic and Prognostic Marker in Lung Cancer. PLoS One. 2016; 11(2):e0148911.
  19. Kang HC, Kim HK, Lee S, Mendez P, Kim JW, Woodard G, Yoon JH, Jen KY, Fang LT, Jones K, Jablons DM, Kim IJ. Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas. Oncotarget. 2016 Feb 16; 7(7):8321-31.
  20. Woodard GA, Jones KD, Jablons DM. Lung Cancer Staging and Prognosis. Cancer Treat Res. 2016; 170:47-75.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.